Hacker News Reader

"Please don't post shallow dismissals, especially of other people's work. A good critical comment teaches us something."

https://news.ycombinator.com/newsguidelines.html

I'll take the bet. I pay you when it "never" does, and you pay me if it ever does. How does $1 and $100 sound?

Engineers are the worst.

The bet might work in your favor. Lots of candiate drugs are discarded for reasons like... having harmful side-effects, being found useless, etc.

Just because something is dismissed today as a promising candidate doesn't prove it'll never be used for something else in the far future. Many toxic drugs later found use in chemotherapy for cancer; it was suddenly good they were toxic

I, too, keep my specifics in the pedantry.

ISRIB is licensed by Calico which recently initiated phase I trials for its use in ALS (https://www.massgeneral.org/news/press-release/investigation...)

ISRIB has toxic effects on the liver, afaik from presentations i have seen. So yeah, unlikely it is going to pass any clinical trial

Wrong, this info I posted is innacurate